Discover the integral role of Global Indirect Treatment Comparison (ITC) Programs in Europe’s Joint Clinical Assessment (JCA) in this insightful piece by EVERSANA. Learn why a global ITC program is not just beneficial but essential for market access and health technology assessment (HTA) submissions. The article delves into the mission of the JCA and the imperative of a global ITC program, especially in areas where direct comparisons are not feasible. It also provides a blueprint for achieving excellence in a global ITC program, emphasizing early engagement, strategic partnerships and analytical depth.
EVERSANA’s HEOR team, with its experience in conducting 400+ ITC analyses and launching 20+ global ITC programs, emerges as an ideal collaborator in this realm. Complete the form below to download the full article to explore more about EVERSANA’s strategic blueprint and their commitment to excellence in global ITC programs
Author
Pamela Vo brings over 18 years of HEOR experience in the pharmaceutical industry, showcasing a history of strategically translating ideas into impactful outcomes. She boasts a proven track record of peer-reviewed publications, significant achievements…
Monique Martin is a seasoned professional with extensive experience spanning over two decades in the pharmaceutical and healthcare industries. Before joining EVERSANA, Monique served as the Global Head of Evidence Synthesis, Modeling and Market…
Dr. Chris Cameron is a global thought leader in health economics and outcomes research with over a decade of experience. Prior to joining EVERSANA, Chris was a partner at Cornerstone Research Group Inc., and…